ESMO TAT Asia 2025: bringing together key stakeholders in early drug development in the Asia-Pacific region

Through collaboration, innovation, and shared expertise, the ESMO TAT Asia Congress aims to bridge the gap between clinicians, academia, regulators and the industry to advance early drug development in oncology and ultimately lead to better cancer care in the region.
Located in Hong Kong SAR, China, a hub for innovative anti-cancer drug development, this meeting will focus on building capacity and accelerating the development of early phase clinical trials, creating strong foundations for oncology drug development.

Join us in Hong Kong SAR, China from 18-20 July for the inaugural TAT Asia Congress.

ESMO TAT Asia 2025 Scientific Co-Chairs